EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-Driven Analysis
For more information about this clinical trial, click here
Schema & Eligibility ECOG-ACRIN EA5163
CoxHealth Medical Center, Springfield, MO
Mercy Hospital, Springfield, MO
Mercy Hospital, St. Louis, MO
Mercy Hospital, Joplin, MO
Ask your physician about participating in this clinical trial or call us.